In the real-world, over a third of patients undergoing lung cancer screening have COPD. Recent research?published in JAMA Health Forum compared the comorbidity profiles from patients in the Personalized Lung Cancer Screening (PLuS) cohort vs. the participants in the National Lung Screening Trial (NLST) and found, in the real-world, lung cancer screening populations are older and sicker than those in the NLST. As compared with the NLST, which launched programs across the country, the (PLuS) cohort study had a higher proportion of participants ages 65 and older (49% vs 26.6%) and the prevalence rates for chronic obstructive pulmonary disease (COPD) in the real-world was (32.7% vs 17.5%, respectively). ?https://lnkd.in/g9sN2kfU
关于我们
CSA Medical, Inc. develops and manufactures the RejuvenAir System, a proprietary interventional liquid nitrogen spray cryotherapy system that utilizes software-driven dosimetry and specialty catheters to enable delivery of cryogen spray inside the airways to flash freeze and destroy damaged cells allowing for a rejuvenative pattern of healing. The RejuvenAir System is approved in the EU and under clinical investigation in the United States. To learn more about our technology or clinical trials, please visit www.rejuvenair.com or www.clinicaltrials.gov [Identifiers: NCT03893370 and NCT03892694].
- 网站
-
https://www.rejuvenair.com
CSA Medical Inc的外部链接
- 所属行业
- 医疗设备制造业
- 规模
- 11-50 人
- 总部
- Lexington，Massachusetts
- 类型
- 私人持股
- 创立
- 2006
- 领域
- Medical device、Minimally invasive、Cryosurgery、Interventional therapy、Interventional Pulmonology、COPD和Chronic Bronchitis
地点
-
主要
获取路线
131 Hartwell Ave
US，Massachusetts，Lexington，02421
CSA Medical Inc员工
-
James McMaster
VP Finance & Administration at CSA Medical Inc.
-
Heather Nigro
SVP, Regulatory/Quality/Clinical Affairs at CSA Medical Inc
-
Paul LaViolette
CEO and Co-Chairman, Pulse Biosciences; Managing Partner, SV Health Investors
-
Chris Ables
Level II Engineer, Installation Supervisor, at CSA Medical Inc
动态
-
Today is World COPD Day. The goal is to raise awareness and present new knowledge and therapeutic strategies for COPD worldwide. World COPD Day is a vital opportunity to raise awareness about chronic obstructive pulmonary disease (COPD). One of those therapies in development is RejuvenAir, a first of its' kind device treatment for COPD with chronic bronchitis. Earlier this year, CSA Medical completed enrollment in its U.S. trial, a critical step toward demonstrating the device’s safety and efficacy. RejuvenAir is under clinical investigation in the U.S. seeking FDA approval. #SPRAYCB, #RejuvenAir, #WorldCOPDDay, #interventionalpulmonology
-
-
Clinical Results backed by Scientific Evidence of Remodeling. RejuvenAir Rejuvenates! #CHEST2024, #COPD, #RejuvenAir, #SPRAYCB
-
ttps://https://lnkd.in/gjFvv8UN
-
-
We're excited to bring new partners on board as we approach the next significant milestone of submitting the?RejuvenAir System for regulatory approval.
The confidence and conviction of our new and existing investors demonstrates the strength of the RejuvenAir platform and potential to change how chronic bronchitis is treated globally.
-
One in six adults in the U.S. with COPD didn’t adhere to their medications due to high costs. If only there was a medical device treatment to address the symptoms of chronic bronchitis associated with COPD. RejuvenAir Metered Cryospray is under clinical investigation in the U.S. seeking FDA approval. #COPD, #chronicbronchitis, #RejuvenAir